|
Tue, 03/02/2021 - 14:35 |
BiondVax Announces Appointment of Amir Reichman as New CEO |
BiondVax Pharma... |
|
Wed, 02/10/2021 - 18:48 |
Lessons learned from COVID-19: The way we develop new medicines is changing |
PhRMA |
|
Thu, 02/04/2021 - 13:24 |
Outlook Therapeutics Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA (bevacizumab-vikg) Through Planned BLA Submission |
Oncobiologics |
|
Thu, 01/28/2021 - 09:03 |
Trevena, Inc. Announces Publication Highlighting OLINVYK Respiratory Safety Data in High-Risk Patients in Pain & Therapy |
Trevena |
|
Wed, 01/27/2021 - 17:22 |
Regulus Announces Addition to Board of Directors |
Regulus Therapeutics |
|
Thu, 01/07/2021 - 10:30 |
Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences |
Trevena |
|
Mon, 12/28/2020 - 14:45 |
Ocular TherapeutixTM Announces Exercise of Underwriters Option to Purchase Additional Shares |
Ocular Therapeutix |
|
Tue, 12/08/2020 - 16:26 |
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity |
Regulus Therapeutics |
|
Sun, 12/06/2020 - 04:37 |
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting |
Xencor |
|
Mon, 11/09/2020 - 15:50 |
Xencor Presents Data from Multiple Preclinical XmAb Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting |
Xencor |
|
Mon, 11/09/2020 - 13:01 |
Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting |
Xencor |
|
Mon, 11/09/2020 - 07:35 |
Heat Biologics Provides Third Quarter 2020 Business Update |
Heat Biologics |
|
Thu, 10/22/2020 - 15:58 |
Retrophin Announces Agreement to Acquire Orphan Technologies |
Travere Therapeutics |
|
Thu, 10/15/2020 - 16:15 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Wed, 10/14/2020 - 01:41 |
Germany: EIB backs Atriva Therapeutics with 24 million for the development of a potential COVID-19 treatment |
European Invest... |
|
Mon, 10/12/2020 - 14:01 |
New Report: The biopharmaceutical industrys sustained commitment to inspiring and advancing tomorrows STEM workforce |
PhRMA |
|
Thu, 10/01/2020 - 21:25 |
Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS Multidisciplinary NET Medical Virtual Symposium |
Xencor |
|
Tue, 09/29/2020 - 11:32 |
CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd |
CASI Pharmaceuticals |
|
Sun, 09/27/2020 - 23:25 |
Catalent Supports Rapid Development and Supply of Nocion Therapeutics Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology |
Catalent |
|
Wed, 09/09/2020 - 14:25 |
Innovative contracts drive access for patients and value for the system |
PhRMA |
|
Tue, 09/08/2020 - 14:51 |
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development |
PhRMA |
|
Wed, 08/26/2020 - 11:02 |
Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results |
Heat Biologics |
|
Mon, 08/17/2020 - 07:40 |
3SBio Maintains Steady Growth in 1H 2020 More than 10 NDAs to be submitted in the next 3 years |
3SBio |
|
Thu, 07/23/2020 - 18:04 |
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome |
Ovid Therapeutics |
|
Mon, 07/13/2020 - 03:21 |
Bristol Myers Squibb Earns Global CEO Cancer Gold Standard Accreditation |
CEO Roundtable ... |
